Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Qlaris Bio, Inc.
Masked, randomized, single site, crossover study to compare 2 concentrations of QLS-101. Subjects will be randomized to one of 2 concentrations of QLS-101 for the first 14 days of daily dosing, and after a 14-day washout period they will be crossed over to the other concentration for another 14 days of daily dosing. Dose assignment is masked to patient and investigator.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with SWS.
Elevated intraocular pressure (IOP)
Willing to continue current dosing regimen of IOP-lowering medications
Willing to refrain from contact lens use in the study eye.
You may not be if
IOP with variability of \> 4 mm Hg
Expected to undergo IOP-lowering surgery
Incisional or laser surgery of any type
Ocular infection, inflammation, clinically significant blepharitis or conjunctivitis
A history of herpes simplex keratitis in either eye.
History of or active clinically significant ocular disease
Use of topical ocular corticosteroids in the 6 weeks prior to Visit 1